Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gomez; Phuong Dinh; Karine Kauria; Veerie Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horvath; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Gunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymur Probachai; Lajos Pusztai

doi:10.1016/S0140-6736(11)61847-3

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gomez, Phuong Dinh, Karine Kauria, Veerie Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horvath, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Gunz, Joo Hyuk Sohn, Vladimir SemiglazovGuillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

Research output: Contribution to journal › Article › peer-review

987 Citations (Scopus)

Original language	English
Pages (from-to)	663-640
Journal	The Lancet
Volume	379
Issue number	9816
DOIs	https://doi.org/10.1016/S0140-6736(11)61847-3
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(11)61847-3

http://www.sciencedirect.com/science/article/pii/S0140673611618473

Cite this

Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gomez, H., Dinh, P., Kauria, K., Van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T-W., Horvath, Z., Coccia-Portugal, M., Domont, J., Tseng, L-M., Gunz, G., Hyuk Sohn, J., ... Pusztai, L. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

Baselga, Jose ; Bradbury, Ian ; Eidtmann, Holger ; Di Cosimo, Serena ; de Azambuja, Evandro ; Aura, Claudia ; Gomez, Henry ; Dinh, Phuong ; Kauria, Karine ; Van Dooren, Veerie ; Aktan, Gursel ; Goldhirsch, Aron ; Chang, Tsai-Wang ; Horvath, Zsolt ; Coccia-Portugal, Maria ; Domont, Julien ; Tseng, Ling-Min ; Gunz, Georg ; Hyuk Sohn, Joo ; Semiglazov, Vladimir ; Lerzo, Guillermo ; Palacova, Marketa ; Probachai, Volodymur ; Pusztai, Lajos. / Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. In: The Lancet. 2012 ; Vol. 379, No. 9816. pp. 663-640.

@article{4631419bc91847438444c0c62966e457,

title = "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial",

author = "Jose Baselga and Ian Bradbury and Holger Eidtmann and {Di Cosimo}, Serena and {de Azambuja}, Evandro and Claudia Aura and Henry Gomez and Phuong Dinh and Karine Kauria and {Van Dooren}, Veerie and Gursel Aktan and Aron Goldhirsch and Tsai-Wang Chang and Zsolt Horvath and Maria Coccia-Portugal and Julien Domont and Ling-Min Tseng and Georg Gunz and {Hyuk Sohn}, Joo and Vladimir Semiglazov and Guillermo Lerzo and Marketa Palacova and Volodymur Probachai and Lajos Pusztai",

year = "2012",

doi = "10.1016/S0140-6736(11)61847-3",

language = "English",

volume = "379",

pages = "663--640",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9816",

}

Baselga, J, Bradbury, I, Eidtmann, H, Di Cosimo, S, de Azambuja, E, Aura, C, Gomez, H, Dinh, P, Kauria, K, Van Dooren, V, Aktan, G, Goldhirsch, A, Chang, T-W, Horvath, Z, Coccia-Portugal, M, Domont, J, Tseng, L-M, Gunz, G, Hyuk Sohn, J, Semiglazov, V, Lerzo, G, Palacova, M, Probachai, V & Pusztai, L 2012, 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial', The Lancet, vol. 379, no. 9816, pp. 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. / Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Kauria, Karine; Van Dooren, Veerie; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Gunz, Georg; Hyuk Sohn, Joo; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymur; Pusztai, Lajos.

In: The Lancet, Vol. 379, No. 9816, 2012, p. 663-640.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

AU - Baselga, Jose

AU - Bradbury, Ian

AU - Eidtmann, Holger

AU - Di Cosimo, Serena

AU - de Azambuja, Evandro

AU - Aura, Claudia

AU - Gomez, Henry

AU - Dinh, Phuong

AU - Kauria, Karine

AU - Van Dooren, Veerie

AU - Aktan, Gursel

AU - Goldhirsch, Aron

AU - Chang, Tsai-Wang

AU - Horvath, Zsolt

AU - Coccia-Portugal, Maria

AU - Domont, Julien

AU - Tseng, Ling-Min

AU - Gunz, Georg

AU - Hyuk Sohn, Joo

AU - Semiglazov, Vladimir

AU - Lerzo, Guillermo

AU - Palacova, Marketa

AU - Probachai, Volodymur

AU - Pusztai, Lajos

PY - 2012

Y1 - 2012

U2 - 10.1016/S0140-6736(11)61847-3

DO - 10.1016/S0140-6736(11)61847-3

M3 - Article

VL - 379

SP - 663

EP - 640

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9816

ER -